Targeting the Membrane-Proximal C2-Set Domain of CD33 for Improved CD33-Directed Immunotherapy

There is increasing interest in targeting CD33 in malignant and non-malignant disorders. In acute myeloid leukemia, longer survival with the CD33 antibody-drug conjugate gemtuzumab ozogamicin (GO) validates this strategy. Still, GO benefits only some patients, prompting efforts to develop more poten...

Descripción completa

Detalles Bibliográficos
Autores principales: Godwin, Colin D., Laszlo, George S., Fiorenza, Salvatore, Garling, Eliotte E., Phi, Tinh-Doan, Bates, Olivia M., Correnti, Colin E., Hoffstrom, Benjamin G., Lunn, Margaret C., Humbert, Olivier, Kiem, Hans-Peter, Turtle, Cameron J., Walter, Roland B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8364569/
https://www.ncbi.nlm.nih.gov/pubmed/33589747
http://dx.doi.org/10.1038/s41375-021-01160-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8364569/
https://www.ncbi.nlm.nih.gov/pubmed/33589747
http://dx.doi.org/10.1038/s41375-021-01160-1

Ejemplares similares